55 related articles for article (PubMed ID: 8152802)
1. Kras-2 alleles, mutations, and lung tumor susceptibility in the mouse--an evaluation.
Fijneman RJ; Ophoff RA; Hart AA; Demant P
Oncogene; 1994 May; 9(5):1417-21. PubMed ID: 8152802
[TBL] [Abstract][Full Text] [Related]
2. Cis-acting genomic elements of the Pas1 locus control Kras mutability in lung tumors.
Manenti G; Trincucci G; Pettinicchio A; Amendola E; Scarfò M; Dragani TA
Oncogene; 2008 Sep; 27(43):5753-8. PubMed ID: 18560355
[TBL] [Abstract][Full Text] [Related]
3. Influence of mouse major histocompatibility complex (H-2) on N-ethyl-N-nitrosourea-induced tumor formation in various organs.
Oomen LC; van der Valk MA; Hart AA; Demant P; Emmelot P
Cancer Res; 1988 Dec; 48(23):6634-41. PubMed ID: 3180072
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis of three-dimensional shape of mouse lung tumors reveals eight lung tumor shape-determining (Ltsd) loci that are associated with tumor heterogeneity and symmetry.
Tripodis N; Demant P
Cancer Res; 2003 Jan; 63(1):125-31. PubMed ID: 12517788
[TBL] [Abstract][Full Text] [Related]
5. Roles of the Pas1 and Par2 genes in determination of the unique, intermediate susceptibility of BALB/cByJ mice to urethane-induction of lung carcinogenesis: differential effects on tumor multiplicity, size and Kras2 mutations.
Karasaki H; Obata M; Ogawa K; Lee GH
Oncogene; 1997 Oct; 15(15):1833-40. PubMed ID: 9362450
[TBL] [Abstract][Full Text] [Related]
6. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
[TBL] [Abstract][Full Text] [Related]
7. Frequent retention of heterozygosity for point mutations in p53 and Ikaros in N-ethyl-N-nitrosourea-induced mouse thymic lymphomas.
Kakinuma S; Nishimura M; Kubo A; Nagai JY; Amasaki Y; Majima HJ; Sado T; Shimada Y
Mutat Res; 2005 May; 572(1-2):132-41. PubMed ID: 15790496
[TBL] [Abstract][Full Text] [Related]
8. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of specific KRAS mutations in lung adenocarcinomas.
Siegfried JM; Gillespie AT; Mera R; Casey TJ; Keohavong P; Testa JR; Hunt JD
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):841-7. PubMed ID: 9332768
[TBL] [Abstract][Full Text] [Related]
10. Co-duplication of olfactory receptor and MHC class I genes in the mouse major histocompatibility complex.
Amadou C; Younger RM; Sims S; Matthews LH; Rogers J; Kumanovics A; Ziegler A; Beck S; Lindahl KF
Hum Mol Genet; 2003 Nov; 12(22):3025-40. PubMed ID: 14506126
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
12. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP
Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793
[TBL] [Abstract][Full Text] [Related]
13. Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors.
Hou SM; Ryk C; Kannio A; Angelini S; Fält S; Nyberg F; Husgafvel-Pursiainen K
Environ Mol Mutagen; 2003; 41(1):37-42. PubMed ID: 12552590
[TBL] [Abstract][Full Text] [Related]
14. Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice.
Nagase H; Mao JH; Balmain A
Cancer Res; 2003 Aug; 63(16):4849-53. PubMed ID: 12941805
[TBL] [Abstract][Full Text] [Related]
15. Haplotype sharing suggests that a genomic segment containing six genes accounts for the pulmonary adenoma susceptibility 1 (Pas1) locus activity in mice.
Manenti G; Galbiati F; Giannì-Barrera R; Pettinicchio A; Acevedo A; Dragani TA
Oncogene; 2004 May; 23(25):4495-504. PubMed ID: 15064703
[TBL] [Abstract][Full Text] [Related]
16. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
[TBL] [Abstract][Full Text] [Related]
17. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
18. Outbred CD-1 mice carry the susceptibility allele at the pulmonary adenoma susceptibility 1 (Pas1) locus.
Manenti G; Galbiati F; Noci S; Dragani TA
Carcinogenesis; 2003 Jun; 24(6):1143-8. PubMed ID: 12807761
[TBL] [Abstract][Full Text] [Related]
19. [Pulmonary carcinogenesis susceptibility-associated single-nucleotide polymorphisms in K-ras intron 2 affect the binding of factor Gata-6 but not gene expression].
Timofeeva OA; Gorshkova EV; Levashova ZB; Kobzev VF; Filipenko ML; Kaledin VI; Merkulova TI
Mol Biol (Mosk); 2002; 36(5):817-24. PubMed ID: 12391845
[TBL] [Abstract][Full Text] [Related]
20. Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers.
Arena S; Isella C; Martini M; de Marco A; Medico E; Bardelli A
Cancer Res; 2007 Sep; 67(18):8468-76. PubMed ID: 17875685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
